There are a few points about these two cases which are of interest.
Both boys have been given the same dose of epanutin, i.e. 1 grains t.d.s. comibined with luminal. In Case 12 the first sign of hyperplasia was noticed after sixteen months under treatment. In Case 11 the exact date of onset is not known but the condition was marked after thirteen months of treatment.
This condition of hyperplasia of gums is not an uncommon accompaniment of epanutin therapy and has been reported since 1938 'by various American and British authors, the first reports coming from the U.S.A. where the drug is used under the name of Dilantin. The percentage of cases affected has been stated to be as high as 55 to 68% by different observers.
The overgrowth of gum tissue appears to be a true hyperplasia (not a hypertrophy) and as it has not occurred in edentulous patients it is thought to arise in the periodontal tissue. Characteristically the growth is of normal colour, painless, and with no tendency to bleed.
It would appear that the hyperplasia is a toxic manifestation, but it does not seem that its occurrence is directly related to the dose of drug used, the length of treatment, or the age of the patient.
Other toxic symptoms reported in cases treated with epanutin are: Nystagmus, diplopia, vertigo and ataxia, mental irritability and confusion, fatigue and apathy, nausea and vomiting, and less commonly cutaneous eruptions. So far none of these has been observed in our two patients.
The diagnosis must, of course, be made from other conditions causing generalized swelling of the gums in children, namely, chronic inflammation, usually associated with mouth-breathing; vitamin C deficiency; congenital (or hereditary) hyperplasia. The latter bears the closest resemblance clinically to epanutin hyperplasia, but it commonly occurs at the time of dentition. The other two conditions can be excluded by the absence of pain and tendency to bleed.
It has been claimed that the hyperplasia tends to disappear on withholding the drug but in view of its great advantages over luminal and other drugs in selected cases of epilepsy, this measure is rarely contemplated unless more unpleasant symptoms are present. In our two cases the question was considered and it was decided that the dramatic success obtained with epanutin in both cases fully justified continuing its administration. In this opinion we were supported by Dr. Tyler Fox of Lingfield epileptic colony where Case 11 lived for several years and where his treatment with epanutin was started.
The possibility of resection of the redundant gum tissue has also been considered and decided against, as, according to present reports, it is likely to be followed by recuirrence with increased rate of growth. Careful supervision of these cases is of course essential, and a close watch should be kept for early neurological or other toxic manifestations. Oral hygiene and regular dental supervision are no less important. Mother alive: apparently toxaemia during all pregnancies. Patient 7th child in family, 1st and 3rd siblings alive and well,but one has megalo-ureters; 2nd, 4th, 5th and 6th siblings stillborn or died in early infancy, two with sarcoma of kidneys, one with hydronephrosis (in this hospital). one cause of death unknown. (Dr. G. S. B. Phillips has kindly supplied details as to the stillborn children.) Paternal grandfather had nephrectomy for calculous pyonephrosis (see family tree).
Patient's history.-Date of birth 26.6.40. Birth-weight 8 lb. 15 oz. Good progress till 9 days old, thereafter vomiting and loss of weight. Attended Queen's Hospital for Children from 11 days old. Vomiting lasted till about 4 weeks old, gain in weight irregular till 2 months-old, thereafter and until present time general progress has been satisfactory. Fracture of left parietal bone at 11 months -old.
Patholoqical examinations.-Urine: No abnormalities found at any time, except at 11 months old when there were a few red cells and pus cells and casts on one occasion.
